# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Updated interim results with an additional ~19 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-t...
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
BTIG analyst Jeet Mukherjee initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Buy rating and announces Pric...
HC Wainwright & Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $10 pr...
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that...
HC Wainwright & Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $10 pr...